Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review  by Khawcharoenporn, T. et al.
Intrathecal colistin for drug-resistant Acinetobacter baumannii central
nervous system infection: a case series and systematic review
T. Khawcharoenporn1, A. Apisarnthanarak1 and L. M. Mundy2
1) Division of Infectious Diseases and Infection Control, Faculty of Medicine, Thammasart University Hospital, Pratumthani, Thailand and 2) LM Mundy, LLC,
Bryn Mawr, PA, USA
Abstract
Treatment limitations exist for drug-resistant Acinetobacter baumannii central nervous system (CNS) infection. We conducted a retro-
spective study and systematic literature review to identify patients with drug-resistant A. baumannii CNS infection who received primary
or adjunct intrathecal or intraventricular (IT/IVT) colistin. In a case series of seven Thai patients and 17 patients identiﬁed in the litera-
ture, clinical and microbiological cure rates with IT/IVT colistin therapy were 83% and 92%, respectively. Three patients (13%) devel-
oped chemical ventriculitis and one (4%) experienced treatment-associated seizures. Death was associated with delayed IT/IVT colistin
therapy compared to survival (mean time from diagnosis to IT/IVT colistin, 7 vs. 2 days; p 0.01). The only independent predictor of
mortality was the severity of illness (APACHE II score > 19, adjusted odds ratio 49.5; 95% CI 1.7–1428.6; p 0.02). This case series sug-
gests that administration of primary or adjunctive IT/IVT colistin therapy was effective for drug-resistant A. baumannii CNS infection.
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Introduction
Acinetobacter baumannii has emerged as an important multi-
drug-resistant (MDR) and pandrug-resistant (PDR) health-
care-associated pathogen [1–4]. Outbreaks caused by MDR
A. baumannii have been reported from various countries,
with anecdotal treatment success using aminoglycosides, car-
bapenems, b-lactamase inhibitors, tigecycline, rifampin and
colistin [1–4]. Although intravenous (IV) carbapenems and
b-lactamase inhibitors reach acceptable drug levels in the
central nervous system (CNS) [5], higher than regular dose
carbapenems in combination with b-lactamase inhibitors,
aminoglycosides or rifampin may not be effective for PDR
A. baumannii CNS infection [3,4].
Patients with CNS infection as a result of PDR A. bauman-
nii isolates susceptible to colistin may beneﬁt from adjunct
intrathecal or intraventricular (IT/IVT) colistin therapy [2–4].
The premise for such a regimen is that IV colistin may not
achieve adequate CNS penetration, IV treatment failures
have been reported, and adverse events related to systemic
treatment include nephrotoxicity and neurotoxicity [2,5,6].
Tigecycline is a potential alternative, yet it is not approved
for meningitis treatment, and CNS pharmacokinetics and
pharmacodynamics require further investigation [7,8]. The
use of IT/IVT colistin and aminoglycosides has been reported
for MDR/PDR A. baumannii meningitis with success rates of
greater than 80% [9–19]. We retrospectively identiﬁed seven
cases of PDR A. baumanni CNS infection treated with IT/IVT
colistin at a Thai hospital and conducted a systematic litera-
ture review and analysis to characterize the epidemiology,
risk factors, clinical manifestations, and outcomes of MDR
and PDR A. baumannii CNS infection treated with IT/IVT
colistin.
Materials and Methods
Case series: patients, study deﬁnitions and data collection
A case patient was deﬁned as a patient who received IT/IVT
colistin therapy between 1 January 2004 and 31 October 2008
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at Thammasat University Hospital, a 500-bed, tertiary-care
hospital in central Thailand. Case identiﬁcation entailed data-
base searches from microbiology, pharmacy and infection
control. A standardized data-gathering instrument was used
for retrospective medical chart review with data harvest of
demographics, underlying medical conditions, neurosurgical
procedures, risk factors, implanted medical devices (IMD),
intensive care unit (ICU) admission, prior antibiotic use,
prior A. baumannii colonization and length of hospitalization
within 3 months of the CNS infection, clinical presentations,
Acute Physiology and Chronic Health Evaluation II (APACHE
II) scores, cerebrospinal ﬂuid (CSF) proﬁles, culture results,
colistin doses, duration of therapy, concurrent antibiotic
therapy, adverse reactions (AEs) to colistin, and outcomes
stratiﬁed by clinical and microbiological cure. The APACHE
II scores were calculated at 24 h before the ﬁrst positive
CSF culture [20]. Bacterial isolation and antimicrobial suscep-
tibility testing were performed in accordance with CLSI
methodology [21]. A diagnosis of A. baumannii CNS infection
was made on the basis of a positive CSF culture obtained
from either ventricular ﬂuid or from lumbar puncture. Acinet-
obacter baumannii was deﬁned as MDR if resistant to all
generations of cephalosporins, ﬂuoroquinolones and amino-
glycosides and PDR if resistant to all cephalosporins, ﬂuor-
oquinolones, aminoglycosides, aztreonem, carbapenems and
sulbactam [22]. Acinetobacter baumannii isolates were consid-
ered susceptible to colistin if the MIC was £2 mg/L and
resistant if the MIC was ‡4 mg/L [21]. Inadequate antimicro-
bial therapy was deﬁned as the receipt of appropriate antibi-
otic therapy with delay (>48 h after the positive CSF
culture) or the receipt of antibiotics that were not active
against the isolated microorganisms [23]. Clinical cure was
deﬁned as resolution of signs and symptoms of CNS infec-
tion, no subsequent need for additional antimicrobial therapy,
and survival at hospital discharge. Microbiological cure was
deﬁned as eradication of A. baumannnii in subsequent cul-
tures. The study was approved by the hospital’s institutional
review board.
Literature review
A comprehensive literature search was performed for
reported cases of MDR or PDR A. baumannii CNS infection
using the Pubmed database from inception through Novem-
ber 2008. The search was restricted to the English language,
using terms ‘multidrug-resistant’, ‘pandrug-resistant’, ‘A. bau-
mannii’, ‘central nervous system’, ‘meningitis’, ‘ventriculitis’,
‘intrathecal’, ‘intraventricular’, ‘colistin’, ‘colistimethate’,
‘treatment’, ‘therapy’, ‘case report’ and ‘review’. References
in each manuscript were reviewed for additional and dupli-
cate case identiﬁcation of MDR or PDR A. baumannii CNS
infection. Eleven articles were identiﬁed, with 17 cases
meeting a case deﬁnition. A structured approach to the data
abstraction included harvest of demographic data, clinical and
laboratory characteristics, treatment and outcomes.
APACHE II scores were not reported in these 17 cases. We
calculated these scores for 14 of the 17 cases for whom clin-
ical and laboratory data were reported; for the other three
cases, we used the median APACHE II score.
Statistical analysis
All analyses were performed using SPSS, version 15.0 (SPSS
Inc., Chicago, IL, USA). Categorical variables were compared
using Pearson’s chi squared or Fisher’s exact test as appro-
priate. Continuous variables were compared using the Wil-
coxon rank-sum test. All p values were two-tailed; p <0.05
was considered statistically signiﬁcant. The primary outcome
was clinical cure. Dependent variables that were present in
more than 10% of patients at a signiﬁcance level of p <0.20
or that had a prior clinical signiﬁcance (e.g. age, APACHE-II
score, receipt of inadequate antimicrobial therapy) were
entered into forward stepwise logistic regression models.
Signiﬁcant variables that were thought to be covariates were
grouped, and only one variable from each group was chosen
for model entry. Adjusted ORs and 95% CIs were calculated
to identify predictors of mortality.
Results
Patient characteristics and risk factors
Seven cases of PDR A. baumanni from the Thai hospital and
17 cases of MDR and PDR A. baumanni from the literature
review were combined for the analysis. The participants’
mean age was 38 years (range 4–74 years), at least 12 of the
24 patients were women, and all (100%) were initially admit-
ted for neurosurgical conditions (Table 1).
Most (n = 17; 71%) participants had either head trauma
or intracranial bleeding and seven (29%) had CNS tumors.
Among 23 cases who had neurosurgery, 19 (83%) had crani-
otomy with external ventricular drain placement; four (17%)
had tumor resection; two (9%) had dural grafting, and one
(4%) had meningeal prosthesis placement. Eight cases (33%)
with underlying medical conditions had either hypertension
(n = 4; 17%), diabetes mellitus (n = 1; 4%), chronic obstruc-
tive pulmonary disease (n = 1; 4%), myocardial infarction
(n = 1; 4%), solid tumor (n = 1; 4%), or prior history of Pseu-
domonas aeruginosa meningitis (n = 1; 4%).
Risk factors for A. baumannii included presence of a CNS
IMD (n = 22; 92%), ICU admission (n = 16; 67%), prior anti-
biotic use (n = 16; 67%), A. baumannii colonization (n = 1;
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8%) and prolonged hospitalization (mean 22 days; range
4–82 days). The most common antibiotic exposures were to
cephalosporins (n = 10; 63% of 16 patients), followed by car-
bapenems (n = 7; 44%), penicillins (n = 5; 31%), vancomycin
(n = 5; 31%), ﬂuoroquinolones (n = 5; 31%), aminoglycosides
(n = 4; 25%), and metronidazole (n = 1; 6%).
Clinical presentations and laboratory results (Tables 1
and 2)
Patients presented with post-operative fever (n = 16; 67%),
altered mental status (n = 9; 38%), headache (n = 7; 29%),
hypotension (n = 3; 13%), and seizures (n = 2; 8%). The
mean APACHE II score was 16 (range 12–22), median blood
leukocyte count was 16 000 cells/lL (range 15 200–
32 000 cells/lL), median CSF leukocyte count was 2100
cells/lL (range 100–40 000 cells/lL); median CSF neutrophil
percentage was 85% (range 68–100%); median CSF glucose
level was 36 mg/dL (range 18–117 mg/dL) and median CSF
protein level was 78 mg/dL (range 39–293 mg/dL). For 12
(50%) of 24 patients, Gram-negative bacilli were reported in
the CSF; three (13%) had concurrent A. baumannii bactera-
emia; 13 (54%) were infected with PDR A. baumannii, nine
(38%) with MDR bacteria and, for two (8%), there was no
report of A. baumannii antimicrobial susceptibility.
Treatment and outcomes (Table 2)
The median time from diagnosis to initiation of IT/IVT colis-
tin treatment was 2 days (range 0–15 days), at a median
dose of 150 000 IU/day (range 40 000–500 000 IU/day) for
the median duration of 15 days (range 2–56 days). Concur-
rent IV antibiotics were administered to 13 (54%) of 24
cases (Table 3). Of these 13 cases, seven (54%) received
TABLE 1. Demographic characteristics, underlying diseases and clinical presentation of patients with multidrug- and pandrug-
resistant Acinetobacter baumannii meningitis who received intrathecal/intraventricular colistin therapy
Case No.
[Reference]
Age in
years/sex
Medical
historya
CNS
diseasea
Type of
surgerya
Risk factors for antibiotic-resistant A. baumanniia
Onset,
daysb PresentationCNS FB
ICU
admission
Prior
ABX
A. baumannii
colonization
1 [Present study] 72/M HTN Head trauma CNT + EVD EVD Yes PCN, MET No 8 F, HA,
shock
2 [Present study] 46/M HTN, ETOH Meningioma CNT + EVD, T EVD Yes PCN, CEP,
FQ, AM
No 30 F, HA
3 [Present study] 33/Fe None SAH CNT + EVD EVD Yes CEP, V No 11 F, HA, AMS
4 [Present study] 64/M HTN, COPD,
solid tumor
Medulloblastoma CNT + EVD EVD Yes PCN, CEP,
FQ, CB
No 28 F, HA, AMS
5 [Present study] 22/M None Head trauma CNT + EVD, EL EVD Yes PCN, CEP No 4 F, HA, AMS
6 [Present study] 41/Fe HTN, DM SAH CNT + EVD EVD Yes CEP No 7 F, HA
7 [Present study] 32/Fe None SAH CNT + EVD EVD Yes CEP No 15 F, HA
8 [9] 74/Fe MI SAH, HC CNT + EVD EVD Yes None No 8 AMS
9 [9] 56/Fe None SAH, HC CNT + EVD;
CNS FB-EVD
Yes None No 11 ND
10 [9] 38/Fe None Head injury CNT + EVD EVD Yes V, CB, AM No 40 ND
11 [9] 26/M None ICH CNT + EVD EVD Yes None Yes 13 ND
12 [9] 4/M None Medulloblasto ma CNT + TR None Yes None No 10 Focal
seizure
13 [10] ND None Head trauma CNT + EVD EVD No IV ABX No ND ND
14 [10] ND None Head trauma CNT + EVD EVD No IV ABX No ND ND
15 [11] 16/M None Haemangioblas
toma
CNT + TR +
EV D
EVD No CEP, AM, CB No 16 F
16 [11] 34/Fe None SAH, HC CNT + EVD EVD No None No 7 F, AMS
17 [12] 29/M None SAH, skull
and C-spine
fractures
CNT + EVD, T EVD Yes CB, FQ, V No 28 F, AMS
18 [13] 38/Fe Peritonitis, UTI BC, HC CNT + EVD EVD No None No ND F, Sepsis
19 [14] 61/Fe Anorectal ulcers Recurrent
meningioma
CNT + EVD,
TR, DG
EVD, DG No CEP, CB No 34 F, shock
20 [15] 41/Fe None SAH CNET + EVD,
aneurysm
clipping
EVD, clips Yes None No 8 F
21 [16] 49/Fe None Recurrent
meningioma
CNET, TR, DG DG Yes PCN, CEP,
CB, FQ, V
No 82 F, AMS
22 [17] 4/ND None Head trauma ND None No None No ND ND
23 [18] 23/Fe None Cervical
meningioma
CNT + EVD,
laminectomy
EVD Yes CB, V, FQ No 13 F, AMS,
seizure
24 [19] 28/M Pseudomonas
meningitis
ICH CNT, meningeal
prosthesis
EVD, meningeal
prosthesis
No CEP, AM,
teicoplanin
No 69 F, AMS
ABX, antibiotics; AM, aminoglycosides; AMS, altered mental status; BC, brain contusion; C, cervical; CB, carbapenems; CEP, cephalosporins; CNS, central nervous system;
CNET, craniectomy; CNT, craniotomy; COPD, chronic obstructive pulmonary disease; DG, dural graft; DM, diabetes mellitus; EL, exploratory laparotomy; ETOH, alcohol
abuse; EVD, external ventricular drainage; F, fever; FB, foreign bodies; Fe, female; FQ, ﬂuoroquinolones; HA, headache; HC, hydrocephalus; HTN, hypertension; ICH, intrace-
rebral haemorrhage; ICU, intensive care unit; IV, intravenous; M, male; MET, metronidazole; MI, myocardial infarction; ND, no data; PCN, penicillins; SAH, subarachnoid
haemorrhage; T, tracheostomy; TR, tumor resection; UTI, urinary tract infection; V, vancomycin.
aWithin the previous 3 months.
bDuration from the day of admission to the onset of meningitis.
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aminoglycosides (amikacin and tobramycin), four (31%)
received colistin, two (15%) received imipenem, two (15%)
received cefoperazone-sulbactam, one (8%) received cipro-
ﬂoxacin, and one (8%) received ampicillin–sulbactam.
IT/IVT colistin was added to the IV antibiotic regimens
because of treatment failure in 11 (85%) of the 13 patients
vs. concurrent initiation of these IV antibiotics in two
patients (15%). The median duration from initiation of ther-
apy to CSF sterilization was 3 days (range 1–23 days). Only
ten participants (seven from our case series and three from
the literature review) underwent IMD removal at the time
of diagnosis, whereas there was no detailed information
regarding IMD removal in the other reported cases. Overall
clinical and microbiological cure rates with IT/IVT colistin
therapy were 83% and 92%, respectively (Table 2). Three
(13%) patients developed chemical ventriculitis and one (4%)
developed dose-related seizures attributed to IT/IVT colistin.
There was no case of nephrotoxicity, other AEs to colistin,
or recurrent infection.
Predictors of mortality
There were no differences between nonsurvival and survival
groups with respect to demographic factors, risk factors
for A. baumannii acquisition, underlying conditions, clinical
TABLE 2. Diagnosis, treatment, and outcome of patients with multidrug- and pandrug-resistant Acinetobacter baumannii
meningitis who received intrathecal/intraventricular colistin therapy
Case No.
[Reference]
CSF proﬁle
Sites of
positive
culture
A. baumannii
strain
IT/IVT colistin Concurrent antibiotics
Time
to CSF
sterilization
(days)a
Adverse
reactions
to IT/IVT
colistin Outcome
WBC
(cell/lL)
/%N
Glucose
(mg/dL)
Protein
(mg/dL) GS Dose
Duration
(days) Types
Duration
(days)
1 [Present
study]
40 000/87 32 222 + CSF PDR 500 000 IU/day 2 CFP-S, CIP 1, 1 Not sterile None Died
2 [Present
study]
8900/70 36 293 + CSF PDR 400 000 IU/day 4 None - Not sterile None Died
3 [Present
study]
4000/100 51 78 + CSF PDR 400 000 IU/day 14 CFP-S 5 15 None Cured
4 [Present
study]
100/86 18 67 + CSF PDR 400 000 IU/day 21 Imipenem 14 10 None Cured
5 [Present
study]
2150/77 26 88 + CSF PDR 500 000 IU/day 15 Imipenem 22 5 None Cured
6 [Present
study]
2450/85 32 76 + CSF PDR 400 000 IU/day 14 None – 3 None Cured
7 [Present
study]
2000/78 31 78 + CSF PDR 300 000 IU/day 18 None – 3 None Cured
8 [9] ND ND ND ND CSF,
EDVT
MDR 125 000 IU/day 18 Amikacin ND 3 None Diedb
9 [9] ND ND ND ND CSF MDR 125 000 IU/day 3 Amikacin ND 3 None Cured
10 [9] ND ND ND ND CSF MDR 125 000 IU/day 12 IV colistin,
amikacin
14, 14 4 CV Cured
11 [9] ND ND ND ND CSF, B,
EVDT
MDR 125 000 IU/day 5 IV colistin,
amikacin
21, 21 1 CV Cured
12 [9] ND ND ND ND CSF, B MDR 50 000 IU/day 24 IV colistin,
amikacin
15, 15 3 CV Cured
13 [10] ND ND ND ND CSF ND 125 000 IU/day 8 None – Sterile None Cured
14 [10] ND ND ND ND CSF ND 250 000 IU/day 10 None – Sterile None Cured
15 [11] 27 900/95 ND ND ND CSF MDR 62 000 IU
twice daily
19 IV tobramycin 21 3 None Diedc
16 [11] 2000/95 ND ND + CSF,
wound
PDR 125 000 IU
twice daily
14 IV tobramycin 14 6 None Cured
17 [12] 110/93 50 78 + CSF PDR 40 000 IU
twice daily
28 None – 3 None Cured
18 [13] 355/ND ND 270 + CSF, PF PDR 75 000 IU
twice daily
14 None – Several
days
Seizure Cured
19 [14] 210/82 117 39 ND CSF PDR 80 000 IU
twice daily
56 IV colistin 56 3 None Cured
20 [15] 2100/ND 69 40 + CSF PDR 300 000 IU
twice daily
21 None – 1 None Cured
21 [16] 130/68 36 136 ND CSF MDR 40 000 IU
twice daily
17 Amphicillin–
Sulbacin
ND 23 None Cured
22 [17] ND ND ND ND CSF MDR 20 doses ND None – Sterile None Cured
23 [18] 3050/ND ND ND + CSF, B PDR 125 000 IU
twice daily
21 None – 2 None Cured
24 [19] ND ND ND ND CSF MDR 40 000 IU
twice daily
42 IVT amikacin 42 Sterile None Cured
B, blood; CFP-S, cefoperazone–sulbactam; CIP, ciproﬂoxacin; CSF, cerebrospinal ﬂuid; CV, chemical ventriculitis; EVDT, external ventricular drain tip; GS, Gram stain; IT,
intrathecal; IV, intravenous; IVT, intraventricular; MDR, multidrug-resistant strain; N, neutrophil; ND, no data; PDR, pandrug-resistant strain; PF, peritoneal ﬂuid; WBC, white
blood cell.
aDuration from the day of IT/IVT colistin initiation to the ﬁrst day of negative CSF culture.
bDeath from myocardial infarction.
cDeath from cardiac arrest.
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presentations or CSF proﬁles. Patients who died had signiﬁ-
cantly higher APACHE II scores (mean score, 20 vs. 15; p
0.003) and received IT/IVT colistin therapy later (mean time
from diagnosis to IT/IVT colistin therapy initiation, 7 vs.
2 days; p 0.01) than those who survived (Table 4). In multi-
variate analysis, the severity of illness, deﬁned as APACHE
score above 19, was the sole predictor of mortality (adjusted
OR 49.5; 95% CI 1.7–1428.6; p 0.02) (Table 5).
Discussion
A. baumannii is typically a healthcare-associated pathogen
associated with a wide range of infections [1,3]. Notably,
post-neurosurgical MDR A. baumanii meningitis increased
from 0% during 1986–1993 to 8% during 1994–2001 in
Taiwan [24]. The ﬁndings of the present study highlight seven
cases of PDR A. baumannii infections from a Thai hospital
between the years 2004–2008 and 17 reported cases in the
literature with a mixture of MDR and PDR A. baumannii phe-
notypes. Fifteen of the 17 (88%) cases from the literature
review were reported in the past decade, implicating an
increase in incidence of drug-resistant A. baumannii CNS
infection coincident with acquisition of resistance genes, a
rise in the proportion and longevity of critically-ill
patients, advances in medicine, and selective pressures of
broad-spectrum antibiotic use [8,25].
Given the emergence of A. baumanni resistance to most
antibiotic classes, carbapenems alone or in combination with
aminoglycosides became the reference standard for empirical
treatment in cases of suspected MDR A. baumannii infection
[2,8]. The emergence of carbapenem-resistant and PDR
A. baumannii strains now suggests that this historical
approach to empirical treatment of infections caused by the
versatile pathogen needs to be reassessed [1–4,8,25]. In one
retrospective study that compared colistin monotherapy to
TABLE 3. Clinical and microbiological cure rates of intrathecal (IT)/intraventricular (IVT) colistin monotherapy or in combina-
tion with systemic antibiotics for treatment of drug-resistant Acinetobacter baumannii meningitis
Regimens References
Number of
patients
Colistin dosea
(duration)
Concurrent
systemic
antibiotics
Clinical cure
ratesb (%)
Microbiological
cure ratesc (%)
IT/IVT colistin monotherapy Present study, 12, 13, 15, 18 11 40 000–400 000
IU/day (14–28 days)
None 10/11 (91) 10/11 (91)
Combined IT/IVT colistin
and systemic antibiotics
Present study, 9, 11, 14, 16 13 40 000–500 000
IU/day (14–56 days)
Ampicillin–sulbactam 10/13 (77) 12/13 (92)
Cefoperazone–sulbactam
Amikacin
Tobramycin
Imipenem
Colistin
Cefoperazone-
sulbactam + ciproﬂoxacin
Colistin and amikacin
aDose units were all converted to IU. Colistin 1 mg equals colistin 30 000 IU and colistimethate 1 mg equals colistin 12 500 IU.
bRates of resolution of signs and symptoms of CNS infection, no subsequent need for additional antimicrobial therapy, and survival until hospital discharge.
cRates of eradication of A. baumannnii in subsequent cultures.
TABLE 4. Factors associated with crude mortality among
patients with multidrug-resistant (MDR) and pandrug-resis-
tant Acinetobacter baumannii meningitis
Characteristics
Nonsurvival
(n = 4)
Survival
(n = 20) p value
Age (years): mean (range) 52 (16–74) 35 (4–64) 0.08
Male sex 3 (75) 7 (35) 0.31
Underlying medical diseasesa 3 (75) 6 (30) 0.58
CNS diseases
Trauma/bleeding 2 (50) 15 (75) 0.55
Tumors 2 (50) 5 (25) 0.55
Clinical presentations
Onsetb, mean days (range) 16 (8–30) 24 (4–82) 0.50
Fever 3 (75) 13 (65) 0.41
Headache 2 (50) 5 (25) 1.00
Mental status change 1 (25) 8 (40) 0.60
Seizure 0 (0) 2 (10) 1.00
Hypotension 1 (25) 2 (10) 1.00
Positive blood culture 0 (0) 3 (15) 1.00
APACHE II score, mean 20 (18–22) 15 (12–22) 0.003
PDR A. baumannii meningitis 2 (50) 11 (55) 1.00
Receipt of inadequate
antimicrobial therapyc
4 (100) 10 (50) 0.53
Time to IT/IVT colistin
initiationd, mean days (range)
7 (3-–15) 2 (0–6) 0.01
IT/IVT colistin therapy
Use as monotherapy 1 (25) 11 (55) 0.59
Dose ‡ 125 000 IU/day 4 (100) 14 (70) 0.54
Duration, mean days (range) 11 (2–19) 19 (3–56) 0.24
Concurrent non-active IV antibiotics 1 (25) 5 (25) 1.00
Data are n (%) of patients, unless otherwise indicated.
APACHE-II, Acute Physiology and Chronic Health Evaluation II; CNS, central
nervous system; IT, intrathecal; IV, intravenous; IVT, intraventricular; NS, nonsig-
niﬁcant.
Bold values signify statistical signiﬁcance (p < 0.05).
aInclude hypertension, alcoholism, chronic obstructive pulmonary diseases, dia-
betes mellitus, solid tumors, peritonitis, urinary tract infection, anorectal ulcers
and Pseudomonas aeruginosa meningitis.
bDuration from the day of admission to the onset of meningitis.
cDelay of receipt of appropriate antibiotic therapy within 48 h after the positive
cerebrospinal ﬂuid culture or receipt of antibiotics that did not have efﬁcacy
against the isolated microorganisms [34].
dDuration from the day of meningitis diagnosis to the day of IT/IVT colistin
therapy initiation.
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colistin plus meropenem in humans, there was signiﬁcantly
higher survival in patients treated with colistin alone,
whereas there were similar rates of nephrotoxicity [26]. In
our review, there were no signiﬁcant differences in cure
rates between IT/IVT colistin monotherapy and combination
therapy with IT/IVT colistin and other IV antibiotics
(Table 3). Because most of the concurrent IV antibiotics
(85%) had failed in the treatment of the infection prior to
IT/IVT colistin therapy, these cure rates likely represent the
effect of IT/IVT colistin therapy rather than that of the IV
antibiotics.
Interest in reﬁned colistin use waned in the early 1980s
and pharmacokinetic and pharmocodynamic data for colistin
are limited. In one study, 25% of the serum concentration of
colistin was detected in CSF and bactericidal activity was
sustained [27]. In 1990, IT/IVT colistin therapy was ﬁrst
reported, yet the optimal dose and duration of therapy
remains undetermined given only anecdotal use in a small
number of reported cases [2,9–19,27]. According to our
review, the clinical and microbiological cure rates were
above 80%, and the commonly administered dose, based on
our experience and other reports, was 40 000–500 000 IU/
day (1 mg of colistin equals 30 000 IU of colistin and 1 mg
of colistimethate equals 12 500 IU of colistin), mixed with
0.9% sodium chloride, given once or twice daily through a
ventricular catheter or a spinal needle after an equivalent
volume of CSF was extracted. For patients with an external
ventricular drain, the drainage was interrupted for 2 h. Dura-
tion of therapy was in a range of 2–3 weeks but may have
varied depending on clinical response, with sterilization of
the CSF expected within 72 h.
The present study demonstrated that high APACHE II
score (>19) and delayed IT/IVT colistin therapy were asso-
ciated with mortality. Other reported predictors of mor-
tality included advanced age, high CSF leukocyte counts,
carbapenemase-producing isolates and receipt of inadequate
therapy [2]. As noted in other studies, early IMD removal
has been associated with survival and should be per-
formed, if feasible, in conjunction with antimicrobial ther-
apy [2]. However, despite of our small sample size and
the best available data from the literature review, we
could not assess the impact of IMD removal on mortality
in the present study.
Colistin treatment regimens were replaced by regimens
with other antibiotics in the 1970s because of nephrotoxicity
and neurotoxicity [28]. However, the incidence of IV colis-
tin-related nephrotoxicity reportedly decreased from 36% in
the 1960s to 14–19% in the period of 1990–2000, and signiﬁ-
cant neurotoxicity attributed to IV colistin has been rare in
the past 15 years [28]. These lower rates of colistin-related
adverse effects (AEs) may be the result of a combination of
the less toxic colistimethate, more meticulous management
of ﬂuid and electrolytes, heightened recognition of colistin
toxicities, and close monitoring of the AEs in clinical practice.
In our review, seizures and chemical ventriculitis were asso-
ciated with IVT/IT colistin therapy, yet it was continued and
clinical recovery was achieved in these cases without seque-
lae from the AEs [9,13].
We acknowledge some notable limitations of the present
study. First, the design had an inherent bias as a result of the
identiﬁcation of cases from a literature review that undoubt-
edly reﬂects publication and information biases. Some data
(responses) were missing from both the retrospective chart
review and published case reports. Hence, we attempted to
minimize information biases and misclassiﬁcation biases using
standardized data-gathering instruments and calculation of the
APACHE II score at the same point of time. Second, although
the severity of illness (APACHE II score) is usually calculated
at the time of admission, a recent study suggested that the
optimal time to measure the severity is 24 h before collection
of the ﬁrst culture-positive sample [20], which is what we did
in this study. The reason is that this time point is close to the
onset of infection and therefore may represent a better
comparative criterion for study participants [20]. Third, the
small number of reported cases of MDR/PDR A. baumannii
limited our ability to detect other potential factors associated
with mortality (e.g. age and IT/IVT colistin therapy initiated
>48 h after diagnosis). Fourth, our study cohort represents a
large number of cases (29%) from our Thai hospital site and
hence the data obtained from this study population may not
be generalized to other populations. Lastly, in two patients in
whom treatment failure was documented microbiologically,
no colistin MIC data were available and the causes of death
were not clearly described. The emergence of A. baumannii
resistance to colistin remains a potential cause of treatment
failure and mortality in such cases.
Table 5. Multivariate logistic regression analysis for predic-
tors of death among patients with multidrug- and pandrug-
resistant Acinetobacter baumannii central nervous system
infections
Variables
Adjusted odds
ratio (95% CI) p value
APACHE II scores > 19a 49.5 (1.7–1428.6) 0.02
Age ‡ 45 years old 10.5 (0.9–92.4) 0.08
IT/IVT colistin therapy
initiated >48 h from diagnosis
6.8 (0.7–60.9) 0.10
IT/IVT, intrathecal/intraventricular.
aAPACHE II score > 19 and receipt of inadequate antimicrobial therapy were
covariated. Only APACHE II scores > 19 were selected in the multivariate
model.
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In conclusion, the ﬁndings obtained in the present study
suggest that IT/IVT colistin therapy is efﬁcacious as either
primary or adjunct treatment of MDR or PDR A. baumannii
CNS infection. Our ﬁndings contribute to an enhanced
understanding concerning the clinical manifestations of this
virulent and versatile, drug-resistant pathogen. Larger obser-
vational studies, if not randomized trials, are needed to
assess the optimal dosage, duration, pharmacokinetic/phar-
macodynamic parameters, effectiveness, and AEs associated
with IT/IVT colistin when used as monotherapy or in combi-
nation with other systemic antibiotics for this CNS infection.
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